Rani Therapeutics reports Q2 2026 results, advances RT-114 oral GLP-1/GLP-2 program
Rani dosed the first participants in an expanded RT-114 cohort, posted early Phase 1a data topping subcutaneous exposure, and said cash covers operations at least through 2027.
SEC filing